Fig. 5.

Dual inhibition of VEGF and EGFR signaling pathways derives more benefits in patients with EGFR amplification or a high tumor mutational load. a Heatmaps show frequent somatic mutations (≥2%) in pretreatment NSCLC samples. Left, gefitinib plus placebo, right, gefitinib plus anlotinib. b The Kaplan–Meier PFS curves of advanced NSCLC patients with blood sample available at baseline c The Kaplan–Meier PFS curves of patients with high (left) and low tumor mutational load (right) treated with gefitinib plus anlotinib versus gefitinib plus placebo. d The Kaplan–Meier PFS curves of patients with (left) or without EGFR amplification (right) who were treated with gefitinib plus anlotinib versus those who were treated with gefitinib plus placebo